Veozah availability in 2026: A provider briefing

If you prescribe Veozah (Fezolinetant) for vasomotor symptoms due to menopause, you're likely fielding patient questions about availability, cost, and alternatives. This briefing covers everything prescribers need to know about the Veozah landscape in 2026.

Veozah — the first NK3 receptor antagonist approved by the FDA — has been on the market since May 2023. While it has not appeared on the FDA drug shortage list, real-world access challenges persist for patients. Understanding the supply chain dynamics, insurance landscape, and available tools can help you support your patients more effectively.

Complete timeline: How we got here

May 2023: FDA approves Veozah (Fezolinetant) 45 mg tablets for the treatment of moderate to severe VMS due to menopause. First-in-class NK3 receptor antagonist. Manufactured by Astellas Pharma.

2023–2024: Market uptake begins. As a novel mechanism with a $550–$765/month price point, pharmacy stocking remains inconsistent. Many pharmacies adopt an order-on-demand model rather than maintaining regular stock.

September 2024: FDA adds updated warning to prescribing information regarding rare but serious liver injury (hepatotoxicity) reported in the postmarketing setting. Boxed warning formalized with specific liver monitoring schedule.

December 2023: Veozah (as Veoza) approved in the European Union.

October 2025: FDA approves elinzanetant (Lynkuet) by Bayer — a dual NK1/NK3 receptor antagonist for moderate to severe VMS. Second nonhormonal NK receptor-targeting option available.

November 2025: Lynkuet becomes commercially available in the United States.

March 2026: Veozah remains available but with ongoing localized access challenges. No FDA shortage listing. No generic competition.

What this means for your prescribing practice

Supply chain status

Veozah's supply chain runs through a single manufacturer (Astellas Pharma) and its wholesale distribution partners. There is no generic equivalent and no competing manufacturer. While Astellas has reported no manufacturing disruptions, the single-source nature of the supply creates inherent vulnerability.

The practical implication: availability is highly pharmacy-dependent. A given pharmacy may or may not stock Veozah based on local demand volume, wholesaler allocation limits, and inventory economics.

Prior authorization complexity

Most commercial payers require prior authorization for Veozah. Common insurer requirements include:

• Diagnosis confirmation: Documentation of moderate to severe VMS due to menopause
• Step therapy: Some plans require documentation of inadequate response to, contraindication to, or intolerance of hormone therapy and/or Brisdelle before approving Veozah
• Liver function verification: Baseline hepatic laboratory values (ALT, AST, bilirubin) must be within acceptable range
• Reauthorization: Typically annual, with documentation of positive clinical response

Medicare Part D plans have variable coverage. The 2025 Part D redesign capped annual out-of-pocket costs at $2,000, which helps limit patient exposure for those whose plans do cover Veozah.

Indication-specific considerations

Veozah is approved only for moderate to severe VMS due to menopause. Prescribing for mild VMS or non-VMS menopausal symptoms (e.g., vaginal atrophy, mood symptoms) is off-label and unlikely to receive payer authorization.

The real-world availability picture

Supply chain mechanics

The path from manufacturer to patient follows a predictable chain: Astellas → wholesale distributor (McKesson, AmerisourceBergen, Cardinal Health) → pharmacy → patient. Disruptions can occur at any point, but the most common bottleneck for Veozah is at the pharmacy stocking level.

Pharmacy-level factors

• Cost of inventory: At $550–$765 per unit, maintaining even modest Veozah stock represents a significant capital allocation for pharmacies
• Demand predictability: Prior authorization delays create lag between prescription and fill, making demand forecasting difficult
• Chain vs. independent: Chain pharmacies use centralized purchasing algorithms that may deprioritize low-volume specialty brands. Independent pharmacies often have more sourcing flexibility.

Cost and access: The numbers your patients are seeing

Pricing overview

• List price: Approximately $550–$765 per 30-day supply (30 tablets, 45 mg)
• With commercial insurance: Copays typically range $30–$150/month depending on formulary tier (usually Tier 3 or 4)
• With VEOZAH Savings Card: Eligible commercially insured patients may pay as little as $0 for the first fill and $30 per refill, with up to $4,000/year in copay assistance
• Medicare Part D: Coverage varies by plan; $2,000 annual OOP cap helps limit exposure
• Uninsured/underinsured: VEOZAH Support Solutions (veozahsupportsolutions.com) provides patient assistance. NeedyMeds and RxAssist may also help connect patients to resources.

Adherence implications

Cost remains a significant barrier to adherence. Among patients who initiate Veozah therapy, out-of-pocket costs and insurance navigation are cited as primary reasons for early discontinuation. Proactively connecting patients with savings programs at the time of prescribing can improve persistence.

Tools and resources for your practice

• Medfinder Provider Portal — Search for pharmacies with Veozah in stock on behalf of your patients. Medfinder's team can contact pharmacies directly and help coordinate prescription fills.
• FDA Drug Shortage Database — Monitor for any future shortage declarations at accessdata.fda.gov
• VEOZAH Support Solutions — veozahsupportsolutions.com offers savings card enrollment, insurance navigation, and patient assistance for your patients
• Astellas Account Manager hotline: 1-866-239-1637 (Monday–Friday, 8 AM–8 PM ET) for formulary and coverage questions

Looking ahead

Several developments are worth monitoring in 2026 and beyond:

• Lynkuet market penetration: As elinzanetant gains traction, it may provide an alternative pathway for patients who can't access Veozah, while also potentially improving overall payer receptivity to NK receptor antagonists as a class
• Payer policy evolution: As real-world evidence accumulates for both Veozah and Lynkuet, step therapy and prior authorization requirements may evolve
• Patent landscape: Veozah's patent protection extends into the 2030s; no generic competition is expected in the near term
• Liver safety monitoring: Postmarketing surveillance data on hepatotoxicity risk will continue to shape prescribing recommendations and patient counseling

Final thoughts

Veozah remains an important nonhormonal option for patients with moderate to severe VMS due to menopause. While it is not in shortage, the single-manufacturer, brand-only, high-cost profile means access challenges are likely to persist.

As prescribers, you can make a meaningful difference by:

1. Proactively connecting patients with the VEOZAH Savings Card at the time of prescribing
2. Using the Medfinder Provider Portal to help patients locate pharmacies with stock
3. Setting realistic expectations about insurance timelines and pharmacy availability
4. Having Lynkuet and other alternatives ready as backup options

For a patient-facing version of this update, share: Veozah shortage update: What patients need to know in 2026.

Also see our provider guide on how to help your patients find Veozah in stock and our guide on helping patients save money on Veozah.